Dr. N. Sreekumaran Nair (Sree) provides scientific advice in the area of statistics in drug development and epidemiology. He plays an important role in mentoring Biostatisticians and Research Physicians. Dr. Nair is Professor of Biostatistics and heads the department of Statistics at Manipal University. He holds responsibility of Statistical Bureau of the university and Secretary of University Research Committee. He is on the executive committee of Indian Society for Medical Statistics and South Asian Cochrane network.
Dr. Nair is a Master in Statistics from Kerala University and Doctorate from Indian Institute of Technology New Delhi. He has trained in epidemiology; controlled clinical trials; issues in clinical trials; medical writing; systematic reviews and meta-analysis from Universities of Monash, Sydney and Queensland.
Dr. Nair started as Biostatistician at National Institute of Immunology, New Delhi and worked on fertility control vaccine trial and leprosy vaccine trial and received institute’s meritorious award. He joined Kasturba Medical College, Manipal as Assistant Professor of Biostatistics and rose to Professor in 2003. In 2006 he came to head the department of Statistics and directed doctoral programs in Biostatistics and Statistics. Dr. Nair chairs the biostatistics board of MPH program. Dr. Nair has attracted research grants from government & industry including Dept of Biotechnology, Bhabha Atomic Research Center, Dept of Science & Technology (DST) and Intel.
Dr. Nair serves as the statistical editor for the Cochrane public health review group and acute respiratory infection group. He is editor of the Bulletin of Indian Society for Medical Statistics. He has 35 publications in national and international journals and conducted more than 50 workshops. Dr. Nair is the recipient of fellowship from Council of Scientific & Industrial Research, DST, Indian Academy of Medical Sciences, Manipal Foundation and Cochrane Collaboration.
Michael Kokesh as Strategic Advisor is responsible for client development from the West Coast of US. He advises the company on marketing and strategic initiatives particularly in US.
Michael is an experienced lawyer, entrepreneur, venture capitalist, and general counsel to private and publicly-traded companies. During his career, Michael has been an executive officer and a member of the board of directors of four successful, venture-financed medical technology companies.
In addition, Michael served from August 2000 until September 2001 as the chief executive officer of the Ischemia Research & Education Foundation (IREF), a scientific research institute and an affiliate of the University of California – San Francisco Medical Center, a company he served as legal counsel from its inception in 1987 until 1996. During that time, Michael also was instrumental in the organization and management of the McSPI Research Institute, a group of leading academic research institutions in 26 countries with more than 100 member physicians.
Through his involvement with IREF and McSPI, Michael is acknowledged as a contributor to several peer reviewed manuscripts published in the New England Journal of Medicine, the Journal of the American Medical Association and other medical society and scientific journals.
Michael is a member of the board of directors of Pericor Therapeutics, a San Francisco and New York-based pharmaceutical company.
A graduate of the University of Colorado – Boulder, Michael received a degree of Bachelor of Arts in Distributive Studies (English literature, Political Science and Molecular Biology) in 1974. He received his degree of Juris Doctor from the University of California – Hastings College of the Law in 1979. In July 2010, Michael was nominated as a Fellow of the American Bar Association Foundation in recognition of his contributions to the legal profession.
Dr. Arvind will guide the company on operational excellence, best practices from the industry and will mentor the leadership team. With his immense experience, he will support the company’s clients medically, scientifically and strategically in their clinical development plan.
Prior to joining EA, Dr. Arvind was the Chief Operating Officer of Clinigene, a full service CRO and a Biocon subsidiary. He worked with Biocon for the past 10 years and has played an integral role in the clinical development of Biocon’s pipeline and contributed to its strategic alliances with global majors. He built a steady clientele for Clinigene which included world’s top pharma and biotech companies.
Prior to joining Biocon, Dr. Arvind was a Consultant Physician with West Wales General Hospital, Carmarthen, Wales and has held several prestigious positions at various reputed hospitals in UK.
Dr. Arvind worked in the capacity of Medical Director and Consultant Physician / Gastroenterologist, Mallya Hospital, Bangalore where he was involved from concept to completion and running of the state of the art Mallya tertiary referral Hospital in India. He was also responsible for the implementation and monitoring of total quality management (clinical governance) of several hospitals.
Dr. Arvind is an FRCP from the Royal Colleges of Physicians, London & Glasgow, MD from Bangalore Medical College and MBA from the University of Birmingham.